Health IT Analytics February 21, 2018
Payers are starting to experiment with value-based care contracts to control the costs of precision medicine while expanding availability of genetic testing.
Precision medicine has started to offer important answers to patients with diseases that have a genetic component, but covering the costs of cutting-edge testing and emerging therapies can be a challenge.
Payers are often hesitant to commit to reimbursing experimental or unproven treatment plans, and many are still on the fence about covering genetic testing, which is often the first step towards finding solutions for rare or complex conditions.
The American Medical Association has already expressed frustration about the mismatch between the progress of precision medicine and its payment.
“Precision medicine tests, technologies and therapeutics are increasingly being...
Today's Sponsors
Today's Sponsor